Autotelic Bio has signed a contract with Yungjin Pharm for co-development and technical implementation of ATB-101, a new and improved combination drug for treating hypertension and diabetes. Through this agreement, Yungjin Pharm will join the clinical trials of ATB-101 and gain non-exclusive sales rights in Korea. Earlier, Jeil Pharmaceutical and Frison also signed a contract for co-development and technical implementation of ATB-101.  

Under the terms of this Agreement, Autotelic Bio will receive an upfront fee, milestone payments based on the progress of development, and royalties based on product sales. Furthermore, Autotelic Bio will share the costs of ongoing clinical trials, reducing the financial burden of development. 

ATB-101, developed by Autotelic Bio, is a fixed- dose combination drug composed of ARB, as antihypertensive agent and SGLT-2, as antidiabetic agent. It aims to increase patient compliance for patients with chronic diseases who suffer from both hypertension and diabetes. Phase 3 clinical trials IND approved for patients with Type 2 diabetes and hypertension from the Korean Ministry of Food and Drug Safety last year, and is currently being studied at more than 25 sites, including the Bundang Seoul National University Hospital, with the goal of submitting an application for NDA next year. 

After securing the safety and efficacy of ATB-101 through Phase 3 clinical trials, AutotelicBio is plan to launch the ATB-101 globally, including in the US, and has obtained patent rights in the US, Japan, Russia, and Korea.